Actually, I think you should delete this post as you have...

First 2 Last

Share
Profile

Follow
BoroBoyinoz

7,588 Posts.

1291

13/01/22

12:37

Post #: 58833128
Share

Originally posted by gmutton ↑

I seem to have re-posted entire thread
Only wanted this to go up
I have reported previous post

https://www.mdpi.com/2673-1991/3/1/4/pdf

Discussion
Regardless of the advances in the medical field, wound infections still pose a significant challenge in a daily routine of a burn ward [3]. One of the most common types of infections in burn patients is through pseudomonas strains. Pseudomonas aeruginosa is a common encapsulated, Gram-negative rod bacterium. It thrives in both aerobic and low oxygen environments and can be found in soil, water, and skin flora. The ability to aggregate and produce a biofilm only increases its resistance to antimicrobial therapy. In our case, coexisting diabetes is also predisposed to a prolonged infection and poor wound healing. In spite of repeated debridements, we were faced with a persistent infection resulting in a total skin loss putting the patient at risk of a bilateral lower leg amputation. A case series of defect reconstructions using NovoSorb BTM from N. S. Solanki et al. [4]showed a high tolerance of the dermal scaffold against infection. In this case, the wound infection was diagnosed after BTM application. Normally no artificial material is recommended in the infected wound ground. To our knowledge and after a literature search using the keywords “novosorb” and “novosorb BTM” in Pubmed, our case report presents the first application of the NovoSorb BTM in the infected wound with Pseudomonas aeruginosa and proved that it could lead to successful treatment. Figure 4. (A) End result by transfer to burn-rehabilitation with almost completely consolidated wounds. (B) Result after burn-rehabilitation with patient being able to freely walk again.

It is disputable if the same effect could be achieved with more thorough and radical debridement and earlier use of Mafenid. We used primarily topical iodine (Braunol) to treat the skin graft infection according to the standard of care in our clinic.
It is to underline that we used NovoSorb BTM as a temporary measure to improve the wound ground win extra time to gain control over the infection and ultimately allow theEur. Burn J. 2022, 3 33 successful autologous skin grafting as a definitive wound coverage. We suspect that the
neovascularized dermal scaffold BTM as intermediary wound coverage allowed for successful treatment of the Pseudomonas aeruginosa infection and subsequent skin grafting [5]
.
Increased inflammatory response properties of BTM, in comparison to Integra® as shown
in the study from P. A. Cheshire et. al, may have helped in the successful treatment [6].

Expand

Actually, I think you should delete this post as you have created a brand new thread with this post, rather than adding to the previous thread that you also created which I assume you want to keep. (I certainly hope you do)

PNV Price at posting: $1.71 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

What's causing the cost-of-living crisis, and how to navigate it